Elkord, E 2007, 'Immunology and immunotherapy approaches for prostate cancer' , Prostate Cancer and Prostatic Diseases, 10 (3) , pp. 224-236.
- Published Version
Restricted to Repository staff only
Download (220kB) | Request a copy
Several mechanisms that impair the immune response to promote tumour progression are reported. These mechanisms aim to reduce the ability of antigen-presenting cells to present antigen and activate naïve T cells to support an active immune response or to create a suppressive environment that induce non-functional tumour-associated antigen-specific T cells. Prostate cancer (PC) alone accounts for 33% of incident cancer cases and about 9% of all cancer-related deaths among men in the USA during 2006. Whereas androgen deprivation has remained the first line of therapy for advanced PC, other therapies are still required due to progression to an androgen-resistant state and eventually loss of control in patients receiving hormonal therapy. Immunotherapy seems to be a promising approach to enhance tumour-specific T-cell responses in different cancers including prostate. More importantly, clinical trials in advanced PC patients have shown that immunotherapy may generate significant clinical responses. Immunology and immunotherapy aspects of PC with focus on prostate-specific antigen will be presented.
|Themes:||Health and Wellbeing|
|Schools:||Schools > School of Environment and Life Sciences > Biomedical Research Centre
Schools > School of Environment and Life Sciences
|Journal or Publication Title:||Prostate Cancer and Prostatic Diseases|
|Publisher:||Nature Publishing Group|
|Depositing User:||E Elkord|
|Date Deposited:||13 Oct 2011 09:43|
|Last Modified:||20 Aug 2013 17:13|
Actions (login required)
|Edit record (repository staff only)|